{"id":163576,"date":"2024-07-09T17:47:11","date_gmt":"2024-07-09T23:47:11","guid":{"rendered":"https:\/\/tecscience.tec.mx\/en\/?p=163576"},"modified":"2024-12-09T13:25:28","modified_gmt":"2024-12-09T19:25:28","slug":"early-disease-detection","status":"publish","type":"post","link":"https:\/\/tecscience.tec.mx\/en\/biotechnology\/early-disease-detection\/","title":{"rendered":"Biomolecular Sensors Aim for Early Disease Detection"},"content":{"rendered":"\n

The development of molecular-level sensors for early detection of lung cancer<\/strong> through blood serum, prior to severe symptoms of the disease, could potentially address this health issue, which proves fatal for many patients<\/strong>.<\/p>\n\n\n\n

SytoSol<\/strong>, a spin-off from the scientific and technological entrepreneurship ecosystem at Tec de Monterrey<\/a>, focuses on advancing healthcare technologies<\/strong>. Their innovations target the next generation of sensors<\/strong> to enhance diagnostic techniques and enable early disease detection<\/a> with greater precision.<\/p>\n\n\n\n

Currently, SytoSol is actively developing products aimed primarily at two conditions: lung cancer and glaucoma<\/strong>. <\/p>\n\n\n\n

Lung cancer is often diagnosed in advanced stages in nearly 80% of patients<\/strong>, with only 30% surviving five years post-diagnosis. Meanwhile, glaucoma, characterized by increased eye pressure<\/strong>, affects over 75 million people worldwide<\/a>, yet half may be unaware of their condition. Delayed treatment can result in complete vision loss for up to 10% of those affected.<\/p>\n\n\n\n

“Our mission is timely detection to facilitate the development of more effective and less invasive therapies for patients<\/a>,” said Sergio Mart\u00ednez<\/a>, researcher and leader at Tec’s scientific and technological entrepreneurship company.<\/p>\n\n\n\n

\n